OncoCyte Corporation (OCX)
NASDAQ: OCX · Real-Time Price · USD
2.900
-0.090 (-3.01%)
Nov 4, 2024, 4:00 PM EST - Market closed
OncoCyte Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Cash & Equivalents | 9.26 | 9.43 | 19.99 | 32.95 | 7.14 | 22.07 | Upgrade
|
| Short-Term Investments | - | - | 0.43 | 0.9 | 0.68 | 0.38 | Upgrade
|
| Cash & Short-Term Investments | 9.26 | 9.43 | 20.43 | 33.85 | 7.82 | 22.45 | Upgrade
|
| Cash Growth | -48.28% | -53.82% | -39.66% | 333.00% | -65.18% | 165.32% | Upgrade
|
| Receivables | 0.09 | 0.48 | 2.01 | 1.44 | 0.2 | - | Upgrade
|
| Prepaid Expenses | 0.6 | 0.64 | 0.98 | 0.9 | 0.26 | 0.08 | Upgrade
|
| Other Current Assets | 0.03 | 0.14 | 2.12 | 2.95 | 0.94 | 0.43 | Upgrade
|
| Total Current Assets | 9.97 | 10.7 | 25.54 | 39.14 | 9.23 | 22.96 | Upgrade
|
| Property, Plant & Equipment | 5.94 | 5.44 | 10.85 | 8.37 | 6.52 | 3.73 | Upgrade
|
| Long-Term Investments | - | - | - | - | 13.42 | 10.96 | Upgrade
|
| Goodwill | - | - | - | 18.68 | 9.19 | - | Upgrade
|
| Other Intangible Assets | 56.55 | 56.6 | 61.63 | 61.72 | 15.01 | - | Upgrade
|
| Other Long-Term Assets | 2.26 | 2.16 | 2.07 | 31.65 | 2.06 | 2.21 | Upgrade
|
| Total Assets | 74.72 | 74.89 | 100.09 | 159.56 | 55.42 | 39.86 | Upgrade
|
| Accounts Payable | 1.05 | 0.95 | 1.25 | 1.81 | 0.43 | 0.47 | Upgrade
|
| Accrued Expenses | 2.8 | 3.22 | 5.61 | 4.91 | 5.75 | 2.62 | Upgrade
|
| Current Portion of Long-Term Debt | - | - | - | 1.31 | 2.39 | 1.13 | Upgrade
|
| Current Portion of Leases | 1.03 | 0.67 | 0.82 | 0.82 | 0.42 | 0.23 | Upgrade
|
| Other Current Liabilities | 2.31 | 2.36 | 4.43 | 5.27 | - | - | Upgrade
|
| Total Current Liabilities | 7.2 | 7.19 | 12.11 | 14.12 | 9 | 4.44 | Upgrade
|
| Long-Term Debt | - | - | - | - | 1.51 | 1.91 | Upgrade
|
| Long-Term Leases | 2.64 | 2.2 | 2.73 | 3.55 | 4.31 | 2.68 | Upgrade
|
| Other Long-Term Liabilities | 42.18 | 39.9 | 45.66 | 76.68 | 7.12 | - | Upgrade
|
| Total Liabilities | 52.02 | 49.3 | 60.5 | 94.35 | 21.94 | 9.02 | Upgrade
|
| Common Stock | 326.2 | 310.3 | 294.93 | 252.95 | 157.16 | 124.58 | Upgrade
|
| Retained Earnings | -303.54 | -289.88 | -260.68 | -187.77 | -123.68 | -93.75 | Upgrade
|
| Comprehensive Income & Other | 0.04 | 0.05 | 0.04 | 0.04 | - | - | Upgrade
|
| Total Common Equity | 22.7 | 20.47 | 34.29 | 65.22 | 33.48 | 30.84 | Upgrade
|
| Shareholders' Equity | 22.7 | 25.59 | 39.59 | 65.22 | 33.48 | 30.84 | Upgrade
|
| Total Liabilities & Equity | 74.72 | 74.89 | 100.09 | 159.56 | 55.42 | 39.86 | Upgrade
|
| Total Debt | 3.67 | 2.87 | 3.54 | 5.68 | 8.63 | 5.94 | Upgrade
|
| Net Cash (Debt) | 5.59 | 6.56 | 16.88 | 28.18 | -0.81 | 16.52 | Upgrade
|
| Net Cash Growth | -62.14% | -61.12% | -40.08% | - | - | 144.92% | Upgrade
|
| Net Cash Per Share | 0.59 | 0.86 | 3.05 | 6.34 | -0.25 | 6.44 | Upgrade
|
| Filing Date Shares Outstanding | 13.37 | 8.27 | 5.93 | 4.61 | 4.45 | 3.12 | Upgrade
|
| Total Common Shares Outstanding | 13.37 | 8.26 | 5.93 | 4.61 | 3.46 | 2.85 | Upgrade
|
| Working Capital | 2.77 | 3.5 | 13.43 | 25.02 | 0.23 | 18.52 | Upgrade
|
| Book Value Per Share | 1.70 | 2.48 | 5.78 | 14.14 | 9.69 | 10.81 | Upgrade
|
| Tangible Book Value | -33.85 | -36.13 | -27.34 | -15.19 | 9.29 | 30.84 | Upgrade
|
| Tangible Book Value Per Share | -2.53 | -4.37 | -4.61 | -3.29 | 2.69 | 10.81 | Upgrade
|
| Machinery | 7.44 | 6.91 | 9.41 | 6.29 | 2.48 | 1.09 | Upgrade
|
| Construction In Progress | 0.36 | 0.73 | 2.14 | 1.24 | 2.09 | 0.13 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.